Steward Partners Investment Advisory’s Evogene EVGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$389 Hold
505
﹤0.01% 4280
2025
Q4
$556 Hold
505
﹤0.01% 4144
2025
Q3
$577 Hold
505
﹤0.01% 4112
2025
Q2
$646 Hold
505
﹤0.01% 3935
2025
Q1
$631 Buy
505
+5
+1% +$8 ﹤0.01% 3828
2024
Q4
$935 Hold
500
﹤0.01% 3766
2024
Q3
$1.53K Hold
500
﹤0.01% 3479
2024
Q2
$3.25K Hold
500
﹤0.01% 3168
2024
Q1
$3.75K Hold
500
﹤0.01% 3132
2023
Q4
$4.2K Hold
500
﹤0.01% 3025
2023
Q3
$2.93K Hold
500
﹤0.01% 2995
2023
Q2
$5.35K Hold
500
﹤0.01% 2771
2023
Q1
$3.15K Hold
500
﹤0.01% 2926
2022
Q4
$3.5K Hold
500
﹤0.01% 2886
2022
Q3
$4K Hold
500
﹤0.01% 2840
2022
Q2
$4K Hold
500
﹤0.01% 2818
2022
Q1
$7K Hold
500
﹤0.01% 2768
2021
Q4
$9K Hold
500
﹤0.01% 2634
2021
Q3
$13K Hold
500
﹤0.01% 2502
2021
Q2
$17K Hold
500
﹤0.01% 5302
2021
Q1
$25.2K Hold
500
﹤0.01% 2359
2020
Q4
$24K Hold
500
﹤0.01% 1982
2020
Q3
$22K Buy
+500
New +$8.93K ﹤0.01% 1853

Other funds holding EVGN

Steward Partners Investment Advisory's EVGN Position: Q1 2026 in Review

Steward Partners Investment Advisory held its Evogene (EVGN) position steady in Q1 2026 at 505 shares worth $389. The position accounts for ﹤0.01% of the portfolio, ranked #4280.

Steward Partners Investment Advisory first reported a position in EVGN in Q3 2020 and has held it in 23 quarters since. The position peaked at $25.2K in Q1 2021. 15 funds tracked by Wall St. Rank hold EVGN as of Q1 2026.

  • Steward Partners Investment Advisory held 505 shares of Evogene worth $389 as of Q1 2026.
  • Steward Partners Investment Advisory left its Evogene share count unchanged in Q1 2026.
  • Evogene made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #4280 holding.
  • Steward Partners Investment Advisory first reported a position in Evogene in Q3 2020 and has held it in 23 quarters since.
  • Steward Partners Investment Advisory's Evogene position peaked at $25.2K in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Evogene as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.